5-(tert-butyldiphenylsilyloxy)-3-hydroxy-3-ethylpentanoic acid | 1056176-31-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 5-(tert-butyldiphenylsilyloxy)-3-hydroxy-3-ethylpentanoic acid
• CAS: 1056176-31-8
• 化学式: C₂₃H₃₂O₄Si
• 分子量: 400.59
• InChiKey: QCHXDBRTNVRCIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.57
• 重原子数：
  28.0
• 可旋转键数：
  9.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66.76
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  5-(tert-butyldiphenylsilyloxy)-3-hydroxy-3-ethylpentanoic acid 在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 以72%的产率得到4-ethyl-4-hydroxy-2-oxotetrahydropyran
  参考文献：
  名称：

  Inhibitors of the mevalonate pathway of streptococcus pneumoniae

  摘要：

  化合物和相关方法可用于选择性麦瓜酸途径抑制剂。

  公开号：

  US20110178043A1
• 作为产物：
  描述：

  1,3-丙酮二羧酸二乙酯 在 氯化锆(IV) lithium aluminium tetrahydride 、 cerium(III) chloride 、 三氟化硼乙醚 、 4-甲基苯磺酸吡啶 、 sodium hydride 、 戴斯-马丁氧化剂 、 N,N-二异丙基乙胺 、 异丙醇 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 丙酮 、 mineral oil 为溶剂， 生成 5-(tert-butyldiphenylsilyloxy)-3-hydroxy-3-ethylpentanoic acid
  参考文献：
  名称：

  Inhibitors of the mevalonate pathway of streptococcus pneumoniae

  摘要：

  化合物和相关方法可用于选择性麦瓜酸途径抑制剂。

  公开号：

  US20110178043A1

文献信息

• Mevalonate analogues as substrates of enzymes in the isoprenoid biosynthetic pathway of Streptococcus pneumoniae
  作者：Takashi Kudoh、Chan Sun Park、Scott T. Lefurgy、Meihao Sun、Theodore Michels、Thomas S. Leyh、Richard B. Silverman

  DOI：10.1016/j.bmc.2009.12.050

  日期：2010.2

  Survival of the human pathogen Streptococcus pneumoniae requires a functional mevalonate pathway, which produces isopentenyl diphosphate, the essential building block of isoprenoids. Flux through this pathway appears to be regulated at the mevalonate kinase (MK) step, which is strongly feedback-inhibited by diphosphomevalonate (DPM), the penultimate compound in the pathway. The human mevalonate pathway is not regulated by DPM, making the bacterial pathway an attractive antibiotic target. Since DPM has poor drug characteristics, being highly charged, we propose to use unphosphorylated, cell-permeable prodrugs based on mevalonate that will be phosphorylated in turn by MK and phosphomevalonate kinase (PMK) to generate the active compound in situ. To test the limits of this approach, we synthesized a series of C-3-substituted mevalonate analogues to probe the steric and electronic requirements of the MK and PMK active sites. MK and PMK accepted substrates with up to two additional carbons, showing a preference for small substituents. This result establishes the feasibility of using a prodrug strategy for DPM-based antibiotics in S. pneumoniae and identified several analogues to be tested as inhibitors of MK. Among the substrates accepted by both enzymes were cyclopropyl, vinyl, and ethynyl mevalonate analogues that, when diphosphorylated, might be mechanism-based inactivators of the next enzyme in the pathway, diphosphomevalonate decarboxylase. (C) 2009 Elsevier Ltd. All rights reserved.